Welcome to our dedicated page for Scilex Holding Co news (Ticker: SCLX), a resource for investors and traders seeking the latest updates and insights on Scilex Holding Co stock.
Scilex Holding Company (Nasdaq: SCLX) generates frequent news at the intersection of non-opioid pharmaceuticals, capital markets activity, and emerging data-tokenization initiatives. The company focuses on acquiring, developing and commercializing non-opioid pain management products for acute and chronic pain and for neurodegenerative and cardiometabolic disease, and its updates often center on this portfolio and related strategic moves.
News about Scilex commonly covers developments around its commercial products ZTlido, ELYXYB and Gloperba, as well as its late-stage candidates SP-102 (SEMDEXA), SP-103 and SP-104. Company announcements highlight clinical milestones, regulatory designations such as Fast Track status for certain candidates, and efforts to advance non-opioid therapies in indications with high unmet needs.
Investors following SCLX news will also see regular coverage of financing and corporate transactions. Recent Form 8-K filings and press releases describe warrant inducement agreements, exercises of existing warrants for cash proceeds, issuance of new warrants, non-recourse loan and securities pledge agreements backed by Scilex or Datavault AI shares, and the termination of an equity line of credit. These items provide insight into how Scilex structures its capital and manages liquidity.
Another recurring news theme is Scilex’s collaboration with Datavault AI. Announcements describe a Securities Purchase Agreement for Datavault AI stock, a pre-funded warrant, and a License Agreement for Datavault’s AI-driven data platforms in biotech and related markets. Press releases also detail Dream Bowl 2026 Meme Coin distributions by Datavault AI to eligible Scilex shareholders and Scilex’s sponsorship of the Dream Bowl 2026 event.
Visitors to this news page can review regulatory disclosures, financing updates, licensing and investment agreements, digital asset-related announcements, and other material events reported in Scilex’s press releases and SEC filings.
Scilex Holding Company (Nasdaq: SCLX) has published the results of its Phase 3 trial for SP-102 (SEMDEXA™) in the PAIN journal. Conducted on 401 patients with lumbosacral radicular pain (sciatica), the trial achieved its primary and key secondary endpoints, showcasing significant pain reduction and improved disability scores with a safety profile comparable to a placebo. The results, first presented at the ASIPP conference in May 2022, indicate that SP-102 could become a important treatment for sciatica, which currently lacks FDA-approved therapies. The study, known as the C.L.E.A.R. trial, confirmed the safety of both single and repeat injections of SP-102, with no serious adverse events reported.
Scilex Holding Company (Nasdaq: SCLX) will present a poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) in San Diego, CA, from June 13-16, 2024. The poster will highlight results from two Phase 3 clinical trials, showing ELYXYB®'s efficacy in migraine patients with insufficient response to triptans. Specifically, 33.3% of patients treated with ELYXYB® achieved 2-hour pain freedom compared to 14.3% with placebo (p=0.0036), with a 200% greater likelihood of achieving pain freedom (OR=3.0). Dr. Richard B. Lipton, Director of the Montefiore Headache Center, will be the presenting author.
For more details, visit the company's website or view the poster presentation online.
Scilex Holding Company (Nasdaq: SCLX) has entered into a commitment letter with Perigrove and Graf Holdings for a $100 million 5-year term financing with royalty-based payments. The funds will be used primarily to repay an existing $85 million senior secured loan from Oramed Pharmaceuticals, with $15 million allocated for general corporate purposes. The financing includes the issuance of a warrant to purchase up to 32.5 million shares of Scilex's common stock at $1.20 per share. If the Commitment is not funded, the deposit will convert into an unsecured loan with a 5-year maturity and an interest rate based on either a percentage of net sales or 12% per year. This financing aims to eliminate existing debt and improve Scilex's cash position, allowing for reinvestment in their commercial products.
Scilex Holding Company, trading on Nasdaq under SCLX, announced the launch of its third commercial product, GLOPERBA®, on June 10, 2024. GLOPERBA® is the first oral liquid medicine for the prophylaxis of gout flares. The product is now available in many national and independent pharmacy chains at a price of $595 per bottle.
Scilex is currently negotiating with additional pharmacy chains to expand distribution. The company emphasizes its commitment to making GLOPERBA® widely accessible across the U.S. Gout, which affects approximately 9.2 million Americans, presents a significant market opportunity, with the U.S. gout treatment market expected to reach $2.0 billion by 2028.
For more details, visit www.gloperba.com.
Scilex Holding Company (Nasdaq: SCLX) announced that the stocking of GLOPERBA®, its third commercial product, is underway in all wholesalers with which it has stocking arrangements throughout the U.S. The process is expected to complete by June 12, 2024. GLOPERBA® is the first and only liquid oral formulation of colchicine for the prophylaxis of gout flares in adults. Scilex has increased the production of GLOPERBA® and supports patients with a co-pay savings card. For more details, visit www.gloperba.com.
Scilex Holding announced FDA approval for the commercial manufacturing of Gloperba®, the first and only liquid colchicine for gout prophylaxis. Launching in the U.S. on June 10, 2024, Gloperba® targets a growing market of 9.2 million gout sufferers. The U.S. gout treatment market may reach $2 billion by 2028. Gloperba® offers flexible dosing, potentially benefiting over 70% of gout patients with comorbid conditions and 17% experiencing severe gastrointestinal side effects from other colchicine forms. Scilex's experienced team and established distribution network will support the launch.
Scilex Holding Company (Nasdaq: SCLX) has sent letters to the U.S. Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA) regarding illegal market manipulation of its common stock. The company alleges that manipulative practices such as 'naked short selling' are being used to devalue its stock, violating SEC Regulation SHO. Scilex Management is committed to combating these illegal activities to protect shareholder value and rights. Copies of the letters can be accessed via the provided links.
Scilex Holding Company (Nasdaq: SCLX) announced it will be added to the MSCI Global Micro Cap Index effective May 31, 2024. This inclusion is expected to enhance visibility for Scilex’s non-opioid pain management therapeutics within global financial markets. MSCI, a leading provider of research and data for investment decision support, acknowledged Scilex’s progress over the past year. The company focuses on developing and commercializing products for acute and chronic pain management and has seen strong investor interest in its innovative clinical-stage portfolio.
Scilex Holding Company (Nasdaq: SCLX) has sent a letter to the U.S. House of Representatives regarding illegal market manipulation of its common stock. The company highlights concerns over 'naked short' selling or maintaining 'naked short' positions, which may violate SEC Regulation SHO. These practices are believed to reduce shareholder value and infringe upon shareholders' rights. Scilex is committed to combating this manipulative and illegal short selling to protect its stock and shareholder interests. Further details can be accessed on Scilex's official website.
Scilex Holding Company (Nasdaq: SCLX) announced final court approval of a settlement agreement with Takeda Pharmaceuticals, resolving a patent infringement lawsuit related to Scilex's intention to expand the label for its liquid colchicine product, Gloperba®. The U.S. District Court for the District of Delaware approved the settlement, allowing Scilex a non-exclusive license to certain Takeda patents. Following this, Scilex requested the FDA convert its tentative approval of the expanded Gloperba® label to final approval.
The expanded label aims to address unmet medical needs, offering specific dosing guidance for patients with renal impairment. Market research shows high interest among rheumatologists for Gloperba®'s precision dosing capabilities. The expanded label would provide dosing flexibility and personalized adjustment options for patients, aligning with American College of Rheumatology guidelines.
FAQ
What is the current stock price of Scilex Holding Co (SCLX)?
What is the market cap of Scilex Holding Co (SCLX)?
